The 5′-nucleotidases are a family of enzymes that catalyze the dephosphorylation of
nucleoside monophosphates and regulate cellular nucleotide and nucleoside levels. While …

Objectives The aims of this manuscript were to review the evidence for the efficacy and
safety of cladribine in multiple sclerosis (MS) and to review the molecular and cellular …

Gene expression analysis may help the management of cancer patients, allowing the
selection of subjects responding to treatment. The aim of this study was the characterization …

The cytotoxic activity of cytarabine (ara‐C) in leukaemic blasts depends on activating
enzymes such as deoxycytidine kinase (dCK) and inactivating enzymes such as the 5 …

We previously established a role for HSP 27 as a predictive marker for therapeutic response
towards gemcitabine in pancreatic cancer. Here, we investigate the underlying mechanisms …

Cladribine was synthesized as a purine analogue drug that inhibited adenosine deaminase.
It received FDA approval in the 1980s for treatment of hairy cell leukemia. Given its toxicity …

Cytosolic 5′-nucleotidase II catalyzes the dephosphorylation of 6-hydroxypurine
nucleoside 5′-monophosphates and regulates the IMP and GMP pools within the cell. It …

In mammalian cells, the process of malignant transformation is characterized by the loss or
down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto …

Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia (AML). After being
transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara …

This review focuses on two chemotherapeutic agents belonging to the family of purine
analogs, 9-β-D-arabinosyl-2-fluoroadenine-5'-monophosphate (F-ara-AMP, fludarabine) …